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4Summary: 
Background: The impact of compliance to clinical practice guidelines (CPG) on 
outcomes and/or costs of care has not been completely clarified. 
Objective: To estimate relationships between medical expenditures and compliance to 
CPG for initial sarcoma treatment. 
Research design: Selected cohorts of patients diagnosed with sarcoma in 2005 and 
2006, and treated at the University hospital and/or the cancer centre of the Rhône-Alpes 
region, France (n=90). Main outcome measurements were: patient characteristics, 
compliance with CPG, health outcomes, and costs. Data were mainly extracted from 
patient records. The logarithm of treatment costs was modelled using linear and Tobit 
regressions. 
Results: Rates of compliance with CPG were 86%, 66%, 88%, 89%, and 95% for initial 
diagnosis, primary surgical excision, wide surgical excision, chemotherapy, and 
radiotherapy, respectively. Total average costs reached €24,439, with €1,784, €11,225, 
€10,360, and €1,016 for diagnosis, surgery (primary and wide surgical excisions), 
chemotherapy, and radiotherapy, respectively. Compliance of diagnosis with CPG 
decreased the cost of diagnosis, whereas compliance of primary surgical excision 
increased the cost of chemotherapy. Compliance of chemotherapy with CPG decreased 
the cost of radiotherapy. 
Conclusion: Since chemotherapy is one of the major cost drivers, these results support 
that compliance with guidelines increases medical care expenditures in short term. 
Key Words: Oncology, Sarcoma, Cost, Clinical guidelines, Efficacy, Medical Practices 
JEL Code: I18 – Government Policy; Regulation; Public Health 
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5Introduction 
Variations in medical practices have been the subject of extensive research [O’ Connor 
et al. 1999; Akhtar et al. 2003; Jagsi et al. 2006; Neils et al. 2007]. In addition to 
medical reasons, these variations are generally explained by the organization of care, the 
level of supply of care and the dissemination of scientific knowledge. In order to reduce 
inappropriate medical practices, numerous Clinical Practice Guidelines (CPG) have 
been developed in recent decades [O’ Connor et al. 2005]. CPG implementation has 
become a priority of healthcare policies and has hence received considerable research 
attention [Kaegi et al. 1991; Audet et al. 1991]. Compliance to CPG has been also 
widely studied even for rare cancers [Chassin et al. 1986; Ray Coquard et al. 1997; Ray 
Coquard et al. 2005]. A retrospective study analyzing the medical records of patients 
with sarcoma in two referent institutions of the Rhone-Alpes region, France (University 
hospital of Lyon and Cancer Center Léon Bérard) had shown that initial clinical 
management between 1999 and 2001 had been consistent with the CPG in only 32% of 
cases [Ray Coquard et al. 2004]. Because of this low percentage and the rarity of the 
tumour, a second study was initiated in 2005 to analyse the evolution of compliance 
over time. As the impact of compliance to CPG on health outcomes and costs of care 
has received less research attention [Fritz et al., 2007], the study initiated in 2005 also 
estimates the links (i) between compliance with CPG and costs of care in the short term; 
(ii) between compliance with CPG, health outcomes, and costs of care in the long term 
(80% of relapses occur during the first three years). The aim of this paper is to present 
the short-run economic analyses performed for comparisons in each referent institution, 
and to assess whether the idea that compliance with CPG generally increases medical 
care expenditures is also valid for rare tumours. In fact, this appears particularly 
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6uncertain for sarcoma due to the clinical specificities (numerous histological subtypes, 
complexity of diagnosis, requirement for multidisciplinary medical decisions, etc.). In 
this disease, for instance, compliance of diagnosis with CPG is expected to decrease the 





All patient aged 15 years and older, with an initial diagnosis of sarcoma made between 
March 2005 and February 2006, and treated at the University Hospital of Lyon and/or at 
the Cancer Centre of the Rhône-Alpes region, France, were eligible for the study. 
 
Exclusion criteria 
Patient treated for a non sarcoma tumour, relapsing patients (no CPG available), 
patients aged less than 15 years, those treated outside the University Hospital of Lyon 
and/or the Cancer Centre of the Rhône-Alpes region, or treated before March 2005 or 
after February 2006 were excluded from the study. 
 
Clinical practice guidelines 
The Clinical Practice Guidelines (CPG) is a nationwide project of the Fédération 
Nationale des Centres de Lutte contre le Cancer (French Federation of Comprehensive 
Cancer Centers, FNCLCC). The CPG for the clinical management of sarcoma used in 
this study were based on Standards-Options and Recommendations (SOR) published in 
1995 and updated in 2004 [FNCLCC 1995].  
L. Perrier et al. Short-Term cost impact of compliance with CPG for sarcoma  
 
7 
Main outcome measurement 
Patient characteristics: In addition to patient age and sex, we also distinguished low, 
intermediate and high-grade tumours. The size and depth of the tumour were noted, as 
well as severe concomitant or past diseases. Three tumour localizations were considered 
(bone, soft tissue, and viscera), as well as three tumour sites (head and/or neck, limb, 
and trunk).  
 
Compliance with CPG:  Each medical procedure was individually assessed for 
conformity with CPG. The CPG for each sequence of treatment are detailed in appendix 
1. Only medical decisions covered by the CPG were taken into consideration for 
assessing compliance. The number of medical decisions judged to be based on 
multidisciplinary medical decision was also taken into account [Ray-Coquard 1997; 
Ray-Coquard 2002; Castel et al. 2004; Ray-Coquard 2005]. Overall treatment was 
considered to be compliant when all treatment sequences were compliant (i.e. diagnosis, 
primary and wide surgical excisions, chemotherapy, and radiotherapy).  
 
Health outcomes: Indicators of efficacy at completion of initial treatment and at one 
year were: complete remission, partial remission, stable disease, progressive disease and 
death.  
 
Cost evaluation: Costs were assessed for each patient and for each sequence of care. 
Costs were calculated from the hospital’s point of view, based on a micro costing 
approach [Drummond et al. 2005]. The time horizon ranged from diagnosis (including 
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8initial biopsy) to end of initial treatment (excluding follow-up period). Thus, for each 
sequence of care and for each patient, the type and quantities of imaging, blood 
transfusion and surgical procedures, as well as the type and length of hospitalisations 
were recorded. The types of initial biopsies, chemotherapy drugs, and radiation 
treatments were also identified. The resources used were then multiplied by unit costs or 
prices, respectively. Estimates were based on 2006 prices and costs. 
 
Data source 
Data related to the characteristics of the patients and the resources used were extracted 
from patient records in the two hospitals. Compliance with CPG was analyzed and 
double-checked by two authors (medical oncologists). Prices were taken from the 
Classification Commune des Actes Médicaux (CCAM) and the Bulletin Officiel de la 
République Française, whereas costs were calculated by the accounting departments of 
the University hospital and the Cancer Centre. 
 
Statistical and econometric analysis 
Descriptive statistics were used to analyze patient characteristics, costs of treatment, and 
health outcomes. Multiple regression analyses were performed to examine the 
relationship between the cost of each treatment sequence and a range of explanatory 
variables, including compliance. The medical variables considered relevant for each 
sequence of initial treatment were retained. Complementary regressions -available upon 
request from the authors- showed that most of these variables were not correlated to 
variations of compliance. Consequently, there was no problem of multicollinearity 
between costs and compliance. The technique for regression analysis depended on the 
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9nature of the data. More precisely, the logarithm of treatment costs at each stage was 
estimated using standard linear models with Ordinary Least Squares (OLS) when the 
cost variable was continuous, and Tobit regression when the cost variable was censored 
so that the data contained a large proportion of zero values. OLS regression is calculated 
as follows:  
i i i u X y + = β    (1) 
where  yi  is the dependent variable, i.e. the log of the total cost, Xi is a vector of 
independent variables, β is a vector of unknown coefficients and ui is an independently 
distributed error term assumed to be normal with zero mean and constant variance σ
2. 










i i i i
i u X if




   (2) 
where ui follows a normal distribution with zero mean and constant variance σ
2. The 
same regressions were also done at a more disaggregated level, i.e. distinguishing the 
different expenditures associated to each sequence. Results are not reported here but are 
available on request from authors.  
As the percentage of radiation therapy was very low, which was in contradiction with 
CPG, regression analysis with radiation therapy was not possible. For all analyses, 
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10Characteristics of patients: Main characteristics of patients are described in table 1. The 
average age of patients at the date of histological examination (n=84) was 54 years, 
ranging from 17 to 86 years. More precisely, 32 patients (38%) were less than 50 years 
old; 33 (39%) were between 50 and 69 years old, 19 (23%) were 70 years old and over. 
Most (57%) patients were female. A majority of high-grade tumours (36%) were 
observed. Only 19 tumours (23%) were low-grade. Sarcomas were mainly located in 
soft tissues (63%) and the most frequent tumour site was the trunk (54%). Most tumours 
were deep-seated (65%) with an average size of 97mm, ranging from 16 to 320mm. 
Tumour size was lower than or equal to 50 mm in 33 % of the patients (n=26) and 100 
mm in 68 % (n=53). Moreover, 23 patients (27%) had other severe concomitant or past 
diseases: 20 previous cancers and 3 severe concomitant diseases such as VIH (n=2) and 
haemophilia (n=1). Twelve patients (14%) had metastases at diagnosis of sarcoma. 
Surgery was contraindicated for 6 patients (7%) in whom the procedure would be too 
mutilating. 
 
Description of patient management: The average time interval between the date of first 
symptoms and the date of diagnosis was 156 days (n=69), ranging from 8 to 1821 days. 
A majority of patients (54%, n=37) were diagnosed with sarcoma between 1 and 3 
months after the first symptoms, and 23% (n=16) received appropriate treatment more 
than three months after the first symptoms. 
Initial sarcoma treatments were as follows: 
-  Thirty patients (36%) were treated with surgery alone. Most of them had low-grade 
tumours (37%), mainly, located in the soft tissues (67%), and the trunk was the most 
frequent tumour site (67%). 
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11-  Eight patients (10%) received only chemotherapy. Most of them had intermediate-
grade tumours (38%), mainly located in the soft tissues (63%), and the trunk was the 
most frequent tumour site (63%). 
-  One patient (1%) with an unknown grade tumour of the soft tissues arising in limb 
received only radiation therapy. 
-  Twelve patients (14%) had both surgery and chemotherapy. Most of them had high-
grade tumours (58%) located equally in the bones, the soft tissues, and the viscera. 
Trunk was the most frequent tumour site (63%). 
-  Twelve patients (14%) had both surgery and radiation therapy. Most of them had 
high-grade tumours (58%), mainly located in the soft tissues (100%), and limb was the 
most frequent tumour site (58%). 
-  Five patients (6%) received both chemotherapy and radiation therapy There was a 
majority of unknown grade tumours (40%), mainly located in the soft tissues (60%), 
and limb was the most frequent tumour site (60%). 
-  Fifteen patients (18%) received all three treatments. Most had high-grade tumours 
(47%), mainly located in the soft tissues (53%), and trunk was the most frequent tumour 
site (40%). 
-  Finally, 1 patient (1%) did not have any treatment because of age. 
 
Diagnosis: All patients underwent complete diagnostic evaluation (imaging, 
consultation with a physician, biopsies, etc.). Fourteen patients (17%) had cytologic 
examination, 12 (15%) had a micro-biopsy, 25 (31%) had a surgical biopsy, 27 (34%) 
had both cytologic examination and a micro-biopsy, 1 patient (1%) had both a micro-
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12biopsy and a surgical biopsy, and 2 patients (2%) underwent all three diagnostic 
procedures.  
Surgery: Primary surgical resection (excluding biopsies) was performed in 68 patients 
(81%): 34 (50%) R0, 25 (37%) R1, and 9 (13%) R2 surgical resections. Eight patients 
(12%) had wide, R0 surgical resections. One patient (1%) underwent surgical resection 
of a metastasis during initial treatment of sarcoma. The surgeons performing these 
procedures (primary and wide surgical excisions) were specialized in digestive and/or 
visceral surgery (42%), in otolaryngology or cardiac, plastic, and neural surgery (26%), 
in cancer surgery (7%), or in orthopaedic and trauma surgery (5%). 
Chemotherapy: Forty patients (48%) received chemotherapy in the neoadjuvant (23 
patients, 57%), adjuvant (11 patients, 28%) or palliative (6 patients, 15%) settings.  
Radiation therapy: Radiation therapy was performed after surgery in 27 patients (82%), 
before surgery in 3 patients (9%), and with palliative intent in 3 patients (9%). 
Lastly, respectively 6 (7%), 14 (17%), and 4 patients (5%) received surgery, 
chemotherapy, and radiation therapy after initial treatment. 
 
Compliance with clinical practice guidelines:  
Initial treatment was compliant with CPG in 41 (53%) cases. More precisely, 
compliance rates were 86% at diagnosis, 66% at primary surgery, 89% at 
chemotherapy, and 95% at radiation therapy. Results are detailed in table 2. 
 
Health outcomes: Main health outcomes at the end of initial treatment and survival rates 
after one year are detailed in table 3. Complete remission was achieved at the end of 
initial treatment in 71% of the patients. At one year, only fifty-one patients (61%) were 
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13still in complete remission, and six of those who were in complete remission at the end 
of initial treatment had died. Amongst the fourteen deaths reported at one year, 13 were 
directly attributable to sarcoma. 
 
Costs of initial treatment: Average costs per treatment sequence are reported in table 4. 
The average cost of initial sarcoma treatment reached €24,439 (n=79), ranging from 
€2,040 to €72,780. The procedures were ranked based on all observed costs, even when 
the cost of a sequence was set at zero. Surgery (primary and wide surgical excisions), 
with an average cost of €11,225, represented 45% of the average total cost. Next came 
chemotherapy (€10,360) with 43% of the average total cost, followed by diagnosis 
(€1,784) with 7%, and radiation therapy (€1,016) with 5%. However, the average cost 
of chemotherapy for the 40 patients who did receive chemotherapy (three missing data 
due to unknown prices for drugs used within clinical trials) reached €22,679. Surgical 
treatment reached €13,535 for the 68 patients who actually had surgery, and the cost of 
radiotherapy was €2,554 for the 33 patients who actually had radiation therapy.  
 
Econometric analyses of treatment costs  
Correlation between costs and medical variables: As shown in table 5, the smaller the 
tumour, the higher the average total cost of diagnosis (p=0.031). Regression analyses at 
a more disaggregated level revealed that the size of the tumour negatively impacted the 
average cost of hospitalization for diagnosis (p=0.015), but did not significantly 
influence the other types of expenditures for this sequence, e.g. expenditures related to 
biopsy or imaging. The depth of the tumour did not significantly influence the average 
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14total cost of diagnosis, even though a deep tumour increased the average cost of 
diagnostic imaging (p=0.001).  
The average total cost of surgery (primary and wide surgical excisions) depended on the 
size and location of the tumour, the presence of metastases at diagnosis, and the 
administration of neoadjuvant treatment: (i) The larger the size of the tumour, the higher 
the average cost (p=0.093). (ii) Average total costs were also higher for tumours arising 
in bone compared to soft tissues (p=0.015). (iii) However, metastases at diagnosis, as 
well as neoadjuvant treatment(s), decreased the average total cost of surgery (p≤0.001). 
At the disaggregated level, all results regarding the average cost of hospitalization for 
surgery were confirmed. Moreover, the average cost of imaging for surgery was higher 
when the site of the tumour was limb compared to head and neck (p=0.061). The mean 
cost of transfusions for surgery increased with the size and the depth of the tumour, as 
well as for intermediate and high grades compared to low grade. 
The average total cost of chemotherapy increased with the occurrence of other diseases 
(p=0.088), for intermediate or high-grade tumours (p<0.001), and with neoadjuvant 
chemotherapy (p<0.001). This cost was also higher for patients with metastases at 
diagnosis (p=0.002). In addition, the younger the patient, the higher the average total 
cost of chemotherapy (p=0.069). Results were confirmed at the disaggregated level for. 
the average costs of chemotherapy drugs, transfusions, and imaging, but not for the 
occurrence of “other diseases” which had no impact on the average costs of imaging. 
However, the tumour site seemed to be an additional determinant influencing the 
average cost of chemotherapy drugs: this cost was smaller for tumours arising in the 
head and/or neck (p=0.076) and in trunk (p=0.096) compared to limb. Average costs of 
hospitalization for chemotherapy were higher for intermediate and high-grade tumours 
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15(p<0.001), for tumours located in bone compared to soft tissues (p=0.067), for younger 
patients (p=0.071) and for patients receiving neoadjuvant chemotherapy (p<0.001). 
Average costs of transfusions for chemotherapy increased only for intermediate and 
high-grade tumours (p=0.008) and for younger patients (p=0.006). 
The average total cost of radiation therapy increased for deep tumours (p=0.004) and for 
intermediate and high-grade tumours (p=0.013). The mean total cost of radiation 
therapy also increased for soft-tissue compared to visceral tumours (p=0.010), and for 
younger patients (p=0.014). 
 
Correlation between costs and compliance to CPG: As shown in table 5, compliance of 
diagnosis with CPG decreased the average total cost of diagnosis (p=0.071). More 
precisely, procedures compliant with CPG reduced the average cost of diagnosis by 
approximately 47% as compared to non compliant ones. This impact of diagnosis 
compliance on the total cost of diagnosis had opposite effects on the different cost items 
associated with diagnosis: the average cost of hospitalization for diagnosis also 
decreased with compliance of diagnosis with CPG (p=0.064), whereas the average cost 
of diagnostic imaging and biopsy increased (p≤0.001). No impact on the costs of other 
sequences of initial sarcoma treatment (surgery, chemotherapy and radiation) was 
observed. 
Compliance of primary surgical resection with CPG did not influence the total cost of 
surgery. However, it was associated with an increased average total cost of 
chemotherapy (p=0.033). We could evaluate this impact by calculating the expected 
value of the log cost (yi) in the model using the following formula: 
) / ( ) / ( ) ( σ β σφ σ β β i i i i X X X y E + Φ =  (3) 
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16where Ф is the cumulative normal distribution function and φ  the standard normal 
density. 
For example, the average total cost of chemotherapy for a 54-year-old patient receiving 
neoadjuvant treatment, without other severe diseases, was 16 times higher when 
primary surgical resection was compliant. There can be two reasons for this: i) 
compliance increased the number of patients who received chemotherapy; ii) 
compliance increased the cost of chemotherapy amongst patients who received 
chemotherapy. The Tobit regression model can be used to evaluate both components 
[McDonald and Moffitt 1980]: 
- the probability of having a positive cost: 
Prob ) / ( ) 0 ( σ β i i X y Φ = >   (4) 
- the value of the cost if it is already above zero: 
)] / ( / ) / ( [ ) 0 ( σ β σ β φ σ β i i i i i X X X y y E Φ + = >  (5) 
For a 54-year-old patient on neoadjuvant treatment, without other severe diseases, the 
probability of receiving chemotherapy was 79% if the primary surgical resection was 
compliant with CPG, and 45% otherwise. For patients undergoing chemotherapy, 
compliance of primary surgery to CPG multiplied the average cost of chemotherapy by 
7.5. 
At the disaggregated level, we noted that compliance of primary surgery with CPG 
increased the main cost items associated with chemotherapy: average cost of drugs 
(p=0.032), hospitalization (p=0.097), and imaging (p=0.028). 
 
Compliance of chemotherapy with CPG did not influence the average cost of 
chemotherapy, whereas it decreased the average total cost of radiotherapy (p=0.031). 
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17The cost reduction associated with compliance of chemotherapy was important: for a 
54-year-old patient with a deep, high-grade tumour, the average total cost of radiation 
therapy was multiplied by 114 when chemotherapy was not compliant. Compliance of 
chemotherapy decreased the probability of having radiation therapy from 91% to 58%. 
 
Discussion 
Compliance with CPG seems to increase the costs of initial treatment 
Considering that compliance of primary surgery (excluding biopsy) significantly 
increases the average total cost of chemotherapy (higher number of patients receiving a 
chemotherapy; higher cost of chemotherapy amongst patients receiving chemotherapy), 
and that compliance of chemotherapy increases the cost of hospitalisation for 
chemotherapy (average length of stay 24.8 versus 13.1 days with and without 
compliance, respectively) and the cost of chemotherapy drugs (3,770€ versus 2,474€ 
with and without compliance, respectively), compliance with CPG seems to increase 
medical expenditures for the initial treatment of sarcoma. As shown in the results, 
chemotherapy is the most expensive treatment sequence because of the cost of 
chemotherapy drugs, i.e. 27% more expensive than diagnosis, surgery and radiation 
therapy together. Our results, like other published studies [Ozminkowski et al. 2000], 
demonstrate that it may be cheaper in the short term to deviate from CPG. However, 
this should not encourage health providers to do so since better care, measured by 
compliance with CPG, could lead to better outcomes in the long term, in particular to 
fewer relapses.  
Following patients longer than one year might help identify cost savings that eventually 
result from better care. However, the literature also suggests that compliance with CPG 
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18decreases costs as, for example, for ischemic stroke management [Quaglini et al. 2004] 
or for patients with acute low back pain [Fritz et al. 2007]. The contradictory results 
reported in the literature regarding compliance with CPG and costs required 
distinguishing between the different treatment sequences. Our results confirm that 
compliance of diagnosis with CPG decreases the average total cost of diagnosis, and 
that compliance of chemotherapy with CPG decreases the average total cost of 
radiotherapy. Moreover, this study is clearly based on “standard CPG” developed by the 
medical profession and used predominantly by physicians with the intent to reduce 
clinical variations and to further enhance the quality of care. The role of the guidelines 
is now expanding and changing whereby more and more guidelines are aimed at the 
reduction of health care costs [Callens et al. 2007]. 
A recent study by J.E. Butrynski et al. based on a large US health insurance database 
from 2002 to 2006 shows an average monthly medical cost of soft tissue sarcoma of 
$3,168 [Butrynski et al. 2008]. In our study sample, a focus on the 53 patients treated 
for soft tissue sarcoma shows an average monthly cost of €3,046 for diagnosis, surgery, 
chemotherapy and radiation therapy (i.e. $3,601 at the January 2006 exchange rate of 
1.18210 euro per US dollar). The cost of care for soft tissue sarcoma reaches $38,016 
per year and per patient in the J.E. Butrynski study, versus $43,207 in our study. 
Surprisingly, the average total cost is higher in France than in the US. Independently of 
numerous biases which could explain these results, the major difference lies with the 
type of treatment received: in the J.E. Butrynski study, respectively 18%, 35%, and 28% 
of the patients received chemotherapy, surgery, and radiation therapy compared to 48%, 
82%, and 39% in our study. Those differences could be a consequence of the 
application of “classic” versus “cost minimisation” guidelines.  
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Relevance of results from the clinical point of view 
Metastases at diagnosis increase the average cost of treatment because the CPG 
advise the use of chemotherapy. On the other hand, neoadjuvant chemotherapy 
decreases the complexity of the surgical procedure, thus reducing the cost of surgery. 
Moreover, younger patients more frequently receive chemotherapy and radiotherapy, 
which increases medical expenditures. This result is in agreement with other studies, 
such as the one showing that older patients generally receive less aggressive anti cancer 
treatments [Battaglia et al., 2006]. As visceral tumours are seldom treated with radiation 
therapy, it appears relevant that average costs of radiation therapy for this localisation 
are lower than for soft tissues. Compared with the results of a medical study performed 
between 1999 and 2001 in the same two hospitals, compliance of primary surgery and 
radiation therapy with CPG increased by 14 points, whereas compliance of 
chemotherapy decreased by 5 points, following the publications of another analysis 
which did not recommend chemotherapy for soft tissue sarcomas [Earl et al. 1998]. As 
shown in the literature, the elaboration of a series of recommendations within the 
framework of a network significantly improved the compliance of practices, and this 
effect persisted over time [Mille et al. 2000; Ray Coquard et al. 2002]. 
 
Limitations of the study 
(1) At one year after the end of initial treatment, the prognosis of sarcoma is generally 
good. This is the reason why this study did not analyse the relation between compliance 
with CPG and health outcomes. Hence our findings cannot, at this stage, support or 
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2004]. 
(2) Comparing hospitals that treat different patient populations, and increasing the 
number of inclusions might provide useful information. In fact, hospitals with fewer and 
weaker patients generally have lower compliance with CPG [Goldman et al. 2007]. 
Increasing the number of inclusions should also permit to include in the regression 
analysis the time between the date of first symptoms and the date of diagnosis, the 
distance between patients’ home and hospital, the speciality of the surgeon, as well as 
the possibility for patients to receive second-line surgery, chemotherapy and/or 
radiation therapy.  
(3) Costs related to the development of the guidelines (data collection, elaboration and 
agreement of CPG) and to their implementation (dissemination of the CPG) were not 
taken into account. Also, due to the high number of variables and the experimental 
design of the study, a non-societal perspective was adopted. However, both limitations 
are generally observed in the literature [Vale et al. 2007].  
 
In conclusion, this study shows multiple correlations between compliance, medical 
variables and costs within and across the sequences (i.e. diagnosis, surgery, 
chemotherapy, and radiation therapy) of initial sarcoma treatment. These results warrant 
further analysis with more patients, more types of hospitals (e.g. non reference 
hospitals), and longer follow-up (80% of relapses occur during the first three years of 
management), especially because (i) compliance of the initial treatment of sarcoma with 
CPG seems to be more expensive in the short run but could reduce medical 
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27Table I 
Characteristics of patients 
 
Characteristics  Mean ±SD or number of patients (%) 
Age (years) at histological evaluation   54.2 ± 18.7 
Male / Female   36 (42.9%) / 48 (57.1%) 
Tumour grade   
Low (grade I)  19 (22.6%) 
Intermediate (grade II)  12 (14.3%) 
High (grade III)  30 (35.7%) 
Unknown / not applicable  11 (13.1%) / 12 (14.3%) 
Tumour site    
Head / neck  11 (13.1%) 
Limb 28  (33.3%) 
Trunk 45  (53.6%) 
Tumour localisation    
Bone 11  (13.1%) 
Soft tissues  53 (63.1%) 
Viscera 20  (23.8%) 
Tumour size in mm
(1)   97.0 ± 70.8 
Tumour depth    
Superficial 6  (7.1%) 
Deep 54  (64.3%) 
Unknown / not applicable  23 (27.4%) / 1 (1.2%) 
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28Other severe diseases (yes/no)  22 (26.2%) / 62 (73.8%) 
Metastasis at diagnosis (yes/no)  12 (14.5%) / 71(85.5%) 
(1) 6 missing data   
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29Table 2 
Compliance with Clinical Practice Guidelines 
 









Diagnosis  72 (85.7%)  12 (14.3%)  - 
Surgery     
- primary surgical resection-  55 (66.3%)  28 (33.7%)  - 
- wide surgical resection-  29 (87.9%)  4 (12.1%)  50 
- metastasis surgery-  11 (100%)  0 (0%)  72 
Chemotherapy  74 (89.2%)  9 (10.8%)  - 
Radiotherapy  74 (94.9%)  4 (5.1%)  - 
Overall  41 (52.5%)  37 (47.5%)  - 
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  At the end of initial treatment (number of observations) 
 
 









Unknown   Total 
Complete  remission  51  1 0  0  0 52 
Partial  remission  0 2  0  0 0  2 
Stable  disease  0 1  4  0 0  5 
Progressive  disease  3 1  0  6 0  10 
Death  6 0  2  6 0  14 
Unknown  0 0  0  0 1  1 
Total  60 5  6  12 1  84 
 Table 4 
Average costs for each sequence (in €) 
 
  Including zero values    Excluding zero values 
Sequence of treatment  n  Mean   (SD)  Range    n  Mean  SD  Range 
Diagnosis  84 1,784  (2,090)  113- 11,360    84  1,784  (2,090)  113- 11,360 
hospitalisation  84 1,410  (2,107)  0-11,019    46  2,575  (2,263)  918 - 11,019 
imaging   84 228  (156)  0-718    82  233  (154)  21 -718 
biopsy   84 82  (39)  0-178    81  86  (36)  53 - 178 
consultation                84 64 (40)  0-90 62 90 - 90
Surgery   82 11,225  (9,792)  0-52,565    68  13,535  (9,174)  1,836 – 52,564 
hospitalisation   82 10,997  (9,461)  0-47,750    68  13,261  (8,816)  1,836 - 47,750 
transfusions   82 177  (607)  0-4,764    14  1,033  (1,157)  176 - 4,764 
imaging   82 51  (99)  0-591    39  107  (120)  13 - 591 
Chemotherapy   81 10,360  (15,332)  0-62,060    37  22,679  (15,535) 4,246 - 62,060 
hospitalisation   81 8,156  (13,186)  0-55,600    35  18,874  (14,172) 2,195 - 55,600 chemotherapy drugs   81 1,767  (3,211)  0-15,904    37  3,867  (3,815)  175 - 15,904 
transfusions   81 194  (553)  0-3,529    19  826  (897)  176 - 3,529 
imaging   81 173  (264)  0-1,146    37  378  (273)  50 - 1,146 
Radiotherapy   83 1,016  (2,547)  0-15,845    33  2,554  (3,546)  753 - 15,845 
Total  79 24,439  (18,072)  2,040 -72,780    79  24,439  (18,072) 2,040 -72,780 
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Regression analysis of the log of total costs for each sequence 
 
  OLS  Tobit I  Tobit I  Tobit I 
Sequence     
                 
             
         
Diagnosis  Surgery  Chemotherapy  Radiation therapy
Coeff. P>|t| Coeff. P>|t| Coeff. P>|t| Coeff. P>|t|
Age  (continuous) 0.00253  0.729 -0.01635 0.469 -0.07938 0.069* -0.13253 0.014**
Grade (1=grade II or III, 0=other)  0.12571  0.616  -0.07290 0.920  6.79740  0.000***  4.82491  0.013** 
Site 1 (1=limb, 0=head/neck)  0.37335  0.419  -0.77919 0.558  -3.45416 0.142  0.50143  0.865 
Site 2 (1=trunk, 0=head/neck)  0.43873  0.333  -1.00811 0.427  -3.39559 0.138  -0.09443 0.974 
Localisation  1  (1=bone,  0=soft  tissue)                 
                 
0.15164 0.732 3.46461 0.015** 2.78043 0.198 0.67666 0.816
Localisation 2 (1=visceral,0=soft tissue)  0.10214  0.765  1.17450  0.233  1.69406  0.416  -8.67329 0.010** 
Tumour size (continuous)   -0.00411 0.031**  0.00919  0.093*  -  -  0.01549  0.261 
Tumour  depth  (1=deep,  0=other) 0.02854 0.914 1.15325 0.125 - - 6.95255 0.004***
Other severe diseases (1=yes, 0=no)  0.01306  0.964  -0.52320 0.540  2.87816  0.088*  -2.25303 0.315 
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Metastasis at diagnosis (1=yes, 0=no)  -0.02786 0.944  -7.46264 0.000***  6.35471  0.002***  -1.74614 0.551 
Neoadjuvant treatment 
(1) - - -3.92367 0.001*** 8.02959 0.000*** 6.95418 0.116
Compliance of diagnosis (1=yes, 0=no)  -0.63056 0.071*  0.44044  0.659  -0.77074 0.763  3.43421  0.268 
Compliance of primary surgery  -  -  -0.85275 0.321  4.54111  0.033**  -1.43287 0.495 
Compliance of chemotherapy      -  -  2.63311  0.244  -6.33505 0.026** 
Constant 7.26377 0.000*** 9.03100 0.000*** -4.31161 0.278 3.01140 0.520
Number  of  observations 77 76 79 76
Number of censored data  NA          
       
12 43 47
 σ                                                                        NA  2.87858  0.267  4.96326  0.657  5.38555  0.806 
Log-likelihood  NA -170.803 -126.638 -107.980
Note. 
(1) Neoadjuvant treatments are: Chemotherapy or radiation therapy when considering surgery regression; Neoadjuvant chemotherapy 
when considering chemotherapy regression; Neoadjuvant radiation therapy when considering radiation therapy regression. 
 *p<0.1; **p<0.05; ***p<0.01 




Main CPG criteria for each sequence of initial sarcoma treatment 
 
Main Criteria for diagnosis: Clinical size and depth of the tumour mass must be recorded; 
Computed Tomography (CT) is required for abdominal localizations, or Magnetic Resonance 
Imaging (MRI) for limb localizations; Chest radiograph or CT scan is required to identify 
metastases; Initial biopsy (incisional or needle), preferably by the surgeon in charge of future 
surgical procedures, is required for bone and soft tissue sarcomas, with the exception of small 
tumours (<3 cm) for which excisional biopsy is considered appropriate.  
Main Criteria for surgery: Whenever possible, primary surgery should involve a wide excision 
with 1–2 cm margins. For high-grade, large (>3 cm) or deep-seated tumours, surgery alone is 
acceptable only in case of amputation or compartimental resection with negative histological 
margins (R0). Wide excision alone, with no adjuvant treatment, is acceptable only for 
superficial, small (<3 cm) and low-grade lesions. Histologically positive margins (R1) or 
incomplete excision (R2) have to be considered inadequate, and should be followed by further 
appropriate treatment.  
Main criteria for chemotherapy: For non-readily operable sarcomas, primary chemotherapy or 
radiation therapy can be an option. For readily operable sarcomas, neo-adjuvant chemotherapy 
should be performed only as part of a clinical research protocol. In the adjuvant setting, systemic 
chemotherapy should be performed only within the context of a prospective clinical trial. 
Adjuvant chemotherapy can be performed for patients with histologically positive margins after 
wide surgical excision. 
Main criteria for radiation therapy: Association of wide surgical excision and adjuvant radiation 
therapy should be considered the standard treatment. The absence of adjuvant radiotherapy is  
acceptable for superficial, small (<3 cm) and low-grade tumours, and for limb sarcomas when 
amputation is performed. For non-operable sarcomas, primary radiation therapy could be an 
option. The optimal treatment strategy involves a 50 Gy delivered dose with an additional boost 
of 10 Gy in case of microscopic residual tumour (R1), with a target volume encompassing the 
tumour bed and surgical scars, including draining orifices, with adapted security margins. 
Moreover, the interval from surgery to radiation therapy must not be longer than 8 weeks. 
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